Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)’s share price traded up 10.2% during trading on Wednesday . The company traded as high as $3.29 and last traded at $3.23, with a volume of 73,668 shares. The stock had previously closed at $2.93.

A number of equities analysts have commented on the stock. Leerink Swann reiterated an “outperform” rating and issued a $7.00 price objective on shares of Aurinia Pharmaceuticals in a report on Wednesday. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th. HC Wainwright assumed coverage on shares of Aurinia Pharmaceuticals in a report on Thursday, June 30th. They issued a “buy” rating and a $7.00 price objective on the stock. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Thursday, May 12th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Aurinia Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $7.15.

The company’s market cap is $105.58 million. The stock’s 50 day moving average price is $2.69 and its 200 day moving average price is $2.58.

Aurinia Pharmaceuticals Inc (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.